drugset / Trial / NCT01330108
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the safety and tolerance of changing patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
Timeline
- Start
- 2011-05
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ambrisentan | Small molecule | 2.5 mg | Oral |
| Subject | Ambrisentan | Small molecule | 5 mg | Oral |
| Subject | Ambrisentan | Small molecule | 10 mg | Oral |